Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648633 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02648633 is a Phase 1 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 4 participants.
The verdict
NCT02648633, a Phase 1 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.
Interventions
- DRUG Nivolumab
- RADIATION Stereotactic Radiosurgery
- DRUG Valproate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648633
The ClinicalTrials.gov registry entry for NCT02648633 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02648633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02648633 about?
NCT02648633 is a clinical study titled "Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma". The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.
What is the current status of trial NCT02648633?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-05-24. Estimated completion is 2017-02-21.
What interventions are being tested in trial NCT02648633?
The interventions under investigation include: Nivolumab (DRUG), Stereotactic Radiosurgery (RADIATION), Valproate (DRUG).
Who is sponsoring clinical trial NCT02648633?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.